Riboxx

Riboxx deve­lops, manu­fac­tures and mar­kets uni­que com­pounds for the immu­no­the­rapy of can­cer or viral dise­a­ses. Riboxx was foun­ded in 2009 by Prof. Dr. med. Jac­ques Roh­ayem and has 2 busi­ness units: The riboxx life sci­en­ces busi­ness unit, for the deve­lo­p­ment, manu­fac­tu­ring and com­mer­cia­liza­tion of mole­cu­lar gene swit­ches and the riboxx phar­maceu­ti­cals busi­ness unit, for the deve­lo­p­ment, manu­fac­tu­ring and com­mer­cia­liza­tion of mole­cu­lar immunoswitches.